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Background: Increased levels of the most electronegative type of LDL, L5, have been observed in the plasma of
patients with metabolic syndrome (MetS) and ST-segment elevation myocardial infarction and can induce endothelial
dysfunction. Because men have a higher predisposition to developing coronary artery disease than do premenopausal
women, we hypothesized that LDL electronegativity is increased in men and promotes endothelial damage.
Methods: L5 levels were compared between middle-aged men and age-matched, premenopausal women with
or without MetS. We further studied the effects of gender-influenced LDL electronegativity on aortic cellular
senescence and DNA damage in leptin receptor–deficient (db/db) mice by using senescence-associated–β-
galactosidase and γH2AX staining, respectively. We also studied the protective effects of 17β-estradiol and
genistein against electronegative LDL–induced senescence in cultured bovine aortic endothelial cells (BAECs).
Results: L5 levels were higher in MetS patients than in healthy subjects (P < 0.001), particularly in men (P = 0.001).
LDL isolated from male db/db mice was more electronegative than that from male or female wild-type mice. In
addition, LDL from male db/db mice contained abundantly more apolipoprotein CIII and induced more BAEC
senescence than did female db/db or wild-type LDL. In the aortas of db/db mice but not wild-type mice, we observed
cellular senescence and DNA damage, and the effect was more significant in male than in female db/db mice.
Pretreatment with 17β-estradiol or genistein inhibited BAEC senescence induced by male or female db/db LDL
and downregulated the expression of lectin-like oxidized LDL receptor-1 and tumor necrosis factor-alpha protein.
Conclusion: The gender dichotomy of LDL-induced cardiovascular damage may underlie the increased
propensity to coronary artery disease in men.
Keywords: Electronegative low-density lipoprotein, Metabolic syndrome, Cardiovascular disease, Aortic senescence,
17β-estradiol, GenisteinBackground
The accelerated development of atherosclerosis and pre-
mature aging of the cardiovascular system have been rec-
ognized in patients with metabolic syndrome (MetS) [1];
however, the underlying mechanisms remain unclear.
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unless otherwise stated.the prodromal stage of atherosclerotic disease, favored
by co-existing harmful stimuli such as dyslipidemia [2].
The potential role of electronegative low-density lipo-
protein (LDL) in cardiovascular diseases is gaining a global
recognition [3-9]. Increased proportions of electronegative
LDL have been described in many conditions that define
metabolic syndrome, such as hypertriglyceridemia [10],
diabetes [4,11], insulin resistance [12], obesity [13], and
hypertension [14]. Previously, we separated plasma LDL
according to charge into 5 subfractions, L1-L5, by using
anion-exchange chromatography and showed that plasma
levels of L5—the most electronegative subfraction of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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elevation myocardial infarction (STEMI) than in healthy in-
dividuals [15]. L5 has a chemical composition unique from
that of other LDL subfractions and has been shown to in-
duce atherogenic processes [16,17], including endothelial
cell apoptosis and mitochondrial dysfunction [18-20].
Although L5 has a role in promoting atherogenesis, it is
not known whether L5 induces endothelial cell senescence,
a pro-inflammatory and prothrombotic phenotype associ-
ated with arterial stiffness [21], endothelial dysfunction
[22], and atherosclerosis [23]. Understanding whether L5
contributes to endothelial cell senescence may help to
explain the accelerated development of atherosclerosis
and the premature aging observed in MetS patients.
The risk of coronary artery disease (CAD) is greater in
men than in premenopausal women [24], but the mecha-
nisms are not completely understood. In addition, the fre-
quency of cardiovascular disease rises in post-menopausal
and in estrogen-deficient women [25]. Because LDL be-
comes more toxic as its electronegativity increases [16],
we hypothesized that LDL electronegativity is higher in
male patients with MetS than in female patients with
MetS and may underlie the increased propensity to CAD
observed in men. In addition, using mice with a proclivity
to developing diabetes and atherosclerosis, we compared
the effects of male and female LDL on cellular senescence
and determined whether estrogen confers protection against
the harmful effects of highly electronegative LDL.Materials and methods
Human L5 study
LDL was isolated from the plasma of asymptomatic,
middle-aged men and age-matched, premenopausal
women who did (MetS patients, n = 30; 15 men and 15
women) or did not (control subjects, n = 26; 11 men and
15 women) meet 3 of the criteria for MetS according to
the National Cholesterol Education Program-Adult Treat-
ment Panel III guidelines [26]. Patients who were taking
medications that may affect the electronegativity of
LDL such as statins, angiotensin-converting enzyme
inhibitors, and angiotensin receptor blockers were
excluded [27]. All participants gave informed consent
for the use of their plasma, and the study was conducted
according to the principles in the Declaration of Helsinki.
Patient characteristics, including waist circumference,
systolic blood pressure, diastolic blood pressure, and levels
of glucose, triglyceride, total cholesterol, high-density
lipoprotein cholesterol (HDL-C), and LDL cholesterol
(LDL-C) were determined according to standard operating
procedures. LDL samples were further resolved into
subfractions L1-L5 by using fast protein liquid chroma-
tography (GE Healthcare, Pittsburgh, PA) with an anion-
exchange UnoQ12 column (BioRad, Hercules, CA).Biochemical analysis of mouse blood plasma
All animal experiments were approved by the China
Medical University Institutional Animal Care and Use
Committee and were performed in accordance with
the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of
Health (NIH Publication No. 85–23, revised 1996).
Whole blood was drawn from mice by means of in-
tubation via the common carotid artery, and plasma
was obtained by using centrifugation. Using an auto-
mated Biochemical Analyzer (SP-4430, Spotchem EZ,
Arkray), we examined plasma levels of glucose, total chol-
esterol, total triglyceride, HDL-C, and LDL-C. LDL (d =
1.030-1.063 g/mL) was isolated by using sequential ultra-
centrifugation as previously described [19]. Protein con-
centrations were determined by using the Lowry method
[16]. The charge of LDL was analyzed by subjecting LDL
samples to gel electrophoresis in 0.7% agarose, and the
composition of delipidated LDL was analyzed by subject-
ing samples to SDS-PAGE. Relative mobility (Rf) was
quantified as a measure of the distance migrated by a band
divided by the distance migrated by the dye front. For
Western blot analysis, proteins were transferred to PVDF
membrane and probed by using antibodies against
apolipoprotein CIII (ApoCIII) and ApoB100 (Academy
Biomedical Company, Inc., Houston, TX). Images were ac-
quired and analyzed by using the G-box imaging system
(Syngene, Frederick, MD). To quantify the protein expres-
sion of ApoCIII, we normalized the band intensity with
that of ApoB100 (internal control).
Analysis of cellular senescence and DNA damage in
mouse aortas
Male and female homozygous leptin receptor knock-out
mice (db/db) and wild-type C57B6/J littermates (controls)
were purchased from The Jackson Laboratory (Bar Harbor,
ME) and were maintained on a 12-hour light/dark cycle
with free access to food and water. After 6 months on a
normal chow diet, all animals were anesthetized by means
of 2% isoflurane inhalation, and the aorta of each mouse
was removed for histologic examination.
For the detection of cellular senescence in the aortic
endothelium, aortas were fixed for 10 minutes at room
temperature in 2% formaldehyde/0.2% glutaraldehyde solu-
tion and were incubated at 37°C for 24 hours with fresh
senescence-associated–β-galactosidase (SA-β-gal) staining
solution (Cell Signaling Technology, Inc., Danvers, MA).
Using images acquired with a Nikon D300s digital camera,
we identified senescent cells marked by a blue color pro-
duced by the enzymatic reaction.
For the detection of DNA damage in the aortic endothe-
lium, thoracic descending aortas were paraffin-embedded,
and serial cross-sections were obtained from each sample.
Slides were immunostained with anti–phospho-histone
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Inc.) and analyzed by using an Olympus IX70 inverted
microscope (Japan) with OPTRONICS digital microscope
cameras (Goleta, CA).
To examine telomerase enzyme activity, aortas or sub-
confluent bovine aortic endothelial cells (BAECs) were ho-
mogenized in 3-[3-(cholamidopropyl) diethylammonio]-1-
propane sulfonate (CHAPS) buffer. Homogenized tissues
were then used to perform telomerase activity assays by
using a modified telomeric repeat amplification protocol
(TRAPeze RT Telomerase Detection Kit; Chemicon, Biller-
ica, MA) according to the manufacturer’s instructions.
Real-time PCR amplification and detection was performed
with StepOnePlus Real-Time PCR Systems (Applied Bio-
systems, Grand Island, NY). Threshold cycle (Ct) measure-
ments were obtained for determining telomerase activity.
Values for Ct, which are inversely related to telomerase ac-
tivity, were then adjusted with the standard curve by using
the commercial TSR8 template.Analysis of cellular senescence in cultured BAECs
Subconfluent BAECs were incubated with a subapoptotic
concentration (30 μg/mL) of LDL from male or female
db/db or wild-type mice for 5 consecutive days. Cells were
then either lysed in radio-immunoprecipitation assay lysis
buffer (Sigma-Aldrich Co., St. Louis, MO) containing pro-
tease inhibitor cocktail and 0.1% Triton X-100 for West-
ern blot analysis or were stained with SA-β-gal for the
detection of senescent cells. A total of 500 cells were
scored in 10 randomly selected fields to determine the
percentage of SA-β-gal–positive cells.
To investigate the protective effects of estrogen against
cell senescence induced by LDL from db/db mice, BAECs








Age (years) 41.2 ± 9.8 48.9 ± 7.1* 49.3 ±
Waist (cm) 88.5 ± 10.6 106.4 ± 12.9** 74.4 ±
SBP (mmHg) 121.3 ± 9.6 136.2 ± 16.5* 120.1
DBP (mmHg) 81.5 ± 10.2 83.4 ± 9.8 73.0 ±
Glucose (mg/dL) 89.2 ± 7.7 142.7 ± 59.1** 85.1
TC (mg/dL) 232.0 ± 47.8 196.9 ± 48.0 224.9
TG (mg/dL) 151.8 ± 95.0 180.9 ± 151.8 106.3
HDL-C (mg/dL) 52.7 ± 15.8 44.0 ± 12.2 62.1 ±
LDL-C (mg/dL) 149.0 ± 37.9 120.9 ± 45.3 142.3
L5 (%) 4.1 ± 5.3 16.9 ± 14.6** 5.1 ±
Values represent the mean ± standard deviation. P-values were determined by usin
syndrome; SBP systolic blood pressure; DBP diastolic blood pressure; TC total choles
**P < 0.01 vs gender-matched control group; #P < 0.05 vs male control group.UK) or its isoflavone analogue genistein (100 nM; LC La-
boratories, MA), followed by exposure with 30 μg/mL
LDL from male or female db/db or wild-type mice. For
the detection of cell senescence, cells were stained with
SA-β-gal as described above.Western blot analysis of lectin-like oxidized LDL receptor-1
(LOX-1) and tumor necrosis factor-α (TNF-α)
Using Western blot analysis, we examined the protein
expression of LOX-1 (antibody from R&D Systems,
Minneapolis, MN) and TNF-α (antibody from Gene-
Tex Inc., Irvine, CA) in BAECs treated with 30 μg/
mL LDL from male db/db mice or PBS in the presence
or absence of pretreatment with 17β-estradiol (10 nM) or
genistein (100 nM), as described previously [19].
Results
The increased percent of L5 in total LDL (L5%) in MetS
patients is more pronounced in men than in women
We examined the L5% in MetS patients and healthy
control subjects (Table 1 and Figure 1) and confirmed
that L5% is significantly higher in MetS patients than
in healthy subjects (P < 0.001). Although no signifi-
cant difference was observed between men in total
LDL-C, men with MetS had significantly higher L5%
than did healthy men (P = 0.001). Furthermore, men
with MetS had higher L5% than did premenopausal
women with MetS, although the difference was not
statistically significant (P = 0.33). Waist circumference
was significantly different between control men and
control women (Table 1; P < 0.05). No other signifi-
cant differences were observed in characteristics be-
tween control men and control women or between










15.7 53.2 ± 4.4 45.9 ± 13.9 51.1 ± 6.2*
8.0# 106.2 ± 15.2** 80.4 ± 11.5 106.3 ± 13.9**
± 26.8 120.2 ± 14.8 120.6 ± 21.0 127.5 ± 17.3
14.6 74.5 ± 9.6 76.6 ± 13.4 78.6 ± 10.5
± 7.4 102.4 ± 19.4** 86.9 ± 7.6 122.5 ± 47.8**
± 60.0 220.0 ± 59.1 227.9 ± 54.2 208.5 ± 54.2
± 95.5 144.1 ± 59.0* 125.6 ± 96.2 162.5 ± 114.7
13.7 54.0 ± 19.2 58.1 ± 15.1 49.0 ± 16.6*
± 52.1 143.9 ± 41.2 145.2 ± 45.9 132.8 ± 44.0
5.6 10.1 ± 8.5* 4.7 ± 5.4 13.5 ± 12.2**
g the Wilcoxon rank sum test (Mann–Whitney U test). MetS metabolic
terol; TG triglyceride; HDL-C HDL cholesterol; LDL-C LDL cholesterol. *P < 0.05,
Figure 1 Percent L5 in total LDL (L5%) among healthy control
subjects and MetS patients, grouped by gender. L5% was
significantly higher in MetS patients than in healthy subjects. In
addition, men with MetS had slightly higher L5% than did women
with MetS. Values for L5% were determined by using fast protein
liquid chromatography. The solid line indicates the mean value for
each group.
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senescence
The db/db mouse is a well-established animal model for
analyzing diabetic dyslipidemia and MetS, which precipi-
tates obesity, insulin resistance, hyperglycemia, and leptin
resistance [28]. We found that male and female db/db
mice had higher body weights and plasma levels of fasting
plasma glucose, total cholesterol, HDL-C, and LDL-C
than did their gender-matched wild-type littermates after
6 months on a normal chow diet (Table 2). However, no
significant differences were observed in these parameters
between male and female db/db mice or between male
and female wild-type mice.
To compare the electronegativity of LDL among male
and female db/db and wild-type mice, we analyzed LDL
samples using agarose gel electrophoresis. In native
agarose gel, LDL from male db/db mice migrated to-
ward the anode faster than did LDL from male or fe-






Body weight (g) 36.50 ± 1.46 62.50 ±
Glucose (mg/dL) 206.88 ± 10.74 398.00 ±
TC (mg/dL) 74.63 ± 4.69 188.88 ±
TG (mg/dL) 47.13 ± 5.78 52.88 ±
HDL-C (mg/dL) 51.00 ± 3.29 97.25 ±
LDL-C (mg/dL) 14.20 ± 1.89 81.05 ± 1
Values represent the mean ± standard error of the mean. TC total cholesterol; TG tr
groups was determined by using the two-independent-sample test with the Mann–
control group. #No parameter was significantly different from that of female mice ofrom male db/db mice was more electronegative than
LDL from wild-type mice. LDL from female db/db mice
was only slightly more electronegative than LDL from
male or female wild-type mice. No significant differences
were observed in LDL electronegativity between males
and females in either wild-type or db/db mice. When we
examined the protein composition of LDL among male
and female db/db and wild-type mice using SDS-PAGE,
we observed a higher content of ApoCIII in db/db mice
than in gender-matched wild-type mice (Figure 2B). These
findings were confirmed by the results of Western blot
analysis for ApoCIII (P < 0.01) (Figure 2C). In LDL from
male db/db mice, ApoCIII levels were significantly higher
than those in LDL from female db/db mice (P < 0.01)
(Figure 2B and C).
To compare the extent of vascular senescence in male
and female db/db and wild-type mice in vivo, aortas from
these mice were fixed and stained with SA-β-gal. SA-β-gal
activity, indicated by blue color, was strong in aortas of
male db/db mice, weak in aortas of female db/db mice, and
absent in aortas of male or female wild-type mice
(Figure 3A). When we examined telomerase activity in
aortas from these mice, we observed significantly lower tel-
omerase activity in the aortas of db/db mice than in those
of wild-type mice, for both genders (P < 0.01). Furthermore,
the telomerase activity in the aortas of male db/db mice
was significantly lower than that in the aortas of female db/
db mice (P < 0.01) (Figure 3B). In addition, aortic cross-
sections stained with anti-γH2AX, indicated by green color,
showed marked DNA damage in the vascular cell nuclei of
male db/db mice that was not observed in male or female
wild-type mice (Figure 3C). Aortic cross-sections of female
db/db mice also showed several positively stained nuclei,
but the percentage was significantly lower than that in
male db/db mice (Figure 3D).
LDL from male db/db mice causes endothelial cell
senescence that can be blocked by estrogens
To test our hypothesis that LDL with increased electro-








3.33** 35.00 ± 0.84 57.80 ± 4.84**
19.89** 219.17 ± 9.04 307.20 ± 41.11*
16.00** 73.17 ± 2.23 183.60 ± 10.80**
6.24 41.33 ± 8.10 49.40 ± 7.05
8.24** 50.83 ± 2.82 89.60 ± 7.92**
1.29** 14.07 ± 4.08 84.12 ± 6.04**
iglyceride; HDL-C HDL cholesterol; LDL-C LDL cholesterol. Variation between
Whitney U test for comparisons. *P < 0.05, **P < 0.01 vs gender-matched
f the same genotype.
Figure 2 Comparison of LDL electronegativity and protein composition between db/db and wild-type mice. A, Representative results of
agarose gel electrophoresis showing the relative electronegativity of LDL isolated from male and female db/db (KO) and wild-type (WT) mice.
Relative mobility (Rf) was compared among groups. B, Representative results of SDS-PAGE showing the relative concentration of ApoCIII in LDL
isolated from male and female db/db (KO) and wild-type (WT) mice. C, Western blot analysis of ApoCIII and ApoB100 protein levels in LDL isolated
from male and female db/db (KO) and wild-type (WT) mice. The ratio of ApoCIII to ApoB100 was compared among groups. n = 5 for each group.
Figure 3 Analysis of cellular senescence and DNA damage in the aortas of db/db and wild-type mice. A, Representative SA-β-galactosidase
staining of senescent cells (blue) in descending thoracic aortas from male and female db/db and wild-type mice. B, Telomerase activity in aortas from
male and female db/db and wild-type mice. C, Representative γH2AX immunostaining (green) of aortic cross-sections from male and female db/db and
wild-type mice. L, lumen. Arrows indicate positive staining. D, The percentage of γH2AX-positive nuclei was compared among groups (n = 8 per group).
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analyzed SA-β-gal staining and telomerase activity in the
treated cells. BAECs treated with LDL from male db/db
mice had a significantly higher percentage of SA-β-gal–
positive stained cells (P < 0.01) and a significantly lower
amount of telomerase activity (P < 0.01) than did BAECs
treated with LDL from male wild-type mice (Figure 4). In
addition, BAECs treated with LDL from female db/db mice
had a significantly higher percentage of SA-β-gal–positive
stained cells (P < 0.01) and a significantly lower amount of
telomerase activity (P < 0.01) than did BAECs treated with
LDL from female wild-type mice, although the effects of
LDL from female db/db mice were not as strong as those
of LDL from male db/db mice (Figure 4). Furthermore,
when we examined whether estrogens confer protection
against LDL from db/db mice, we found that pretreat-
ment of BAECs with 17β-estradiol (10 nM) or genistein
(100 nM) significantly attenuated the percentage of
SA-β-gal–stained cells and blocked the effects onFigure 4 Effect of LDL electronegativity and estrogens on bovine aor
SA-β-gal staining of senescent BAECs (blue) 5 days after incubation with 30
the presence or absence of pretreatment with 17β-estradiol (10 nM) or genist
activity in BAECs treated with LDL from male or female db/db or wild-type mi
group. *P < 0.01 vs. gender-matched wild-type LDL, #P < 0.05 and ##P < 0.01 vtelomerase activity induced by LDL from male or female
db/db mice (P < 0.01 or P < 0.05) (Figure 4).Toxicity induced by LDL from male db/db mice is
mediated by increased TNF-α and LOX-1 expression in
endothelial cells
To study the specific mechanisms underlying the effects
of LDL and estrogen on vascular senescence, we exam-
ined LOX-1 and TNF-α expression in BAECs treated
with LDL from male db/db mice in the presence or
absence of pretreatment with 17β-estradiol or genistein
(Figure 5A and B). In BAECs treated with LDL from male
db/db mice, LOX-1 and TNF-α protein levels were
significantly upregulated when compared with those in
PBS-treated cells (P < 0.05). In addition, pretreatment with
17β-estradiol or genistein decreased LOX-1 and TNF-α
protein expression induced by LDL from male db/db mice
(P < 0.05 vs. LDL-treated cells; Figure 5A and B).tic endothelial cell (BAEC) senescence. A, Representative images of
μg/mL LDL isolated from male or female db/db or wild-type mice in
ein (100 nM). B, The percentage of senescent cells and (C) telomerase
ce in the presence or absence of 17β-estradiol or genistein. n = 4 for each
s. gender-matched db/db LDL.
Figure 5 LOX-1 and TNF-α expression in bovine aortic endothelial cells (BAECs) treated with LDL and/or estrogens. A, Representative
Western blot showing LOX-1 and TNF-α protein expression in BAECs treated with LDL from male db/db mice (mdbLDL) in the presence or
absence of pretreatment with 100 nM genistein (Gen) or 10 nM 17β-estradiol (E2). B, Quantification of protein expression shown in (A), expressed
as a percent ratio to the expression of β-actin (internal loading control) (n = 4). *P < 0.05 vs control-treated BAECs, #P < 0.05 vs. mdbLDL-treated BAECs.
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Significance of increased LDL electronegativity in men
with MetS compared to women with MetS
Cardiovascular disease differs between men and women.
Among men and women aged 20 to 44, the prevalence
of cardiovascular disease is one-third higher in men
than in women (34% versus 24%, respectively) [29]. In a
middle-aged group of MetS subjects, we found that in-
creased plasma L5 levels in these subjects are more pro-
nounced in men than in women, which may explain
why men are at higher cardiovascular risk than are
women and require early medical treatment, such as
statin administration. In addition, in male mice with
MetS, we observed increased LDL electronegativity
compared to wild-type mice. We found in mice with
MetS and in cultured BAECs that gender corresponded
with the extent of vascular senescence. Interestingly, we
observed a protective effect of 17β-estradiol or genistein
against electronegative LDL–induced senescence. Our
findings collectively suggest that gender disparities in LDL
electronegativity may underlie the increased propensity to
CAD in men.Potential contribution of increased ApoCIII content to the
harmful effects of electronegative LDL
When fed a Western diet, db/db mice have an atherogenic
lipoprotein profile characterized by increased levels of
VLDL cholesterol and LDL-C [30]. Consistent with the
findings of a previous study, we found that male and fe-
male db/db mice fed for 6 months with a standard chow
diet showed evidence of weight gain, hyperglycemia, and
hypercholesterolemia [31]. However, these traits did not
differ between our male and female db/db mice and, thus,
cannot explain the differences observed in vascular senes-
cence in these animals.
We previously showed that plasma levels of L5 are
higher in patients with diabetes mellitus than in healthy
subjects [18] and that levels of the most electronegative
subfraction of very-low-density lipoprotein, called V5,
are higher in patients with MetS than in healthy subjects
[32]. Recently, a clinical study, Prospective Urban RuralEpidemiology (PURE), of South Africans showed that
some dietary fatty acids affect blood lipid profiles more
unfavorably in men than in women [33]. To further
characterize gender-influenced lipid abnormalities that
occur in diabetes and MetS, we compared the electro-
negativity of LDL and the content of ApoCIII between
male and female db/db mice and isogenic wild-type
mice. LDL from male db/db mice was more electronega-
tive than LDL from wild-type mice and contained more
ApoCIII than did LDL from female db/db mice or wild-
type mice. In addition, in each group of mice, ApoCIII
content was greater in the LDL that induced more signifi-
cant vascular senescence, indicating that ApoCIII may be
one of the components of highly electronegative LDL
responsible for its harmful effects. It has been well-
established that ApoCIII is atherogenic and contributes
to vascular senescence and coronary heart disease [34].
ApoCIII plays a pivotal role in regulating lipoprotein
metabolism by inhibiting receptor-mediated uptake by
the liver, which leads to the accumulation of triglycer-
ides in ApoCIII-containing lipoproteins [35]. Other
toxic components of LDL previously associated with
MetS include oxidized LDL, small dense LDL, and other
modified forms of LDL [36,37]. However, copper-
oxidized LDL is artificially derived, and, although small
dense LDL is a plausible concept, neither has yet to be
isolated from the plasma for mechanistic scrutiny. ApoB
has also been reported to be associated with MetS [38,
39]. In a previous study, we found that L5 contains frag-
mented ApoB100, which is most likely a consequence of
longer LDL residence times in the circulation [40].Protective role of female hormones against the harmful
effects of electronegative LDL
Among women, the cardiovascular death rates are 3 times
higher after menopause than before menopause [41], indi-
cating a protective role for female hormones that decline
with age. In addition, the presence of type 2 diabetes ag-
gravates cardiometabolic risk in postmenopausal women,
as demonstrated by more atherogenic lipid and proinflam-
matory profiles [42]. In patients with type 1 diabetes,
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obesity and dyslipidemia) have also been observed, which
may result from different outcomes after treatment be-
tween male and female patients [43]. In our in vivo and
in vitro experiments, we found that female db/db aortas
exhibited less cellular senescence than did male db/db aor-
tas, and LDL isolated from female db/db mice caused less
BAEC senescence than did LDL from male db/db mice.
Furthermore, 17β-estradiol or genistein reduced db/db
LDL–induced senescence. The differences observed be-
tween male and female db/db mice, combined with our
evidence for a protective role of estrogens, indicate that fe-
male hormones may protect the arterial endothelium
against senescence in vivo, either by altering the electro-
negativity of LDL or by inhibiting electronegative LDL re-
ceptor–mediated signaling pathways, such as the LOX-1
signaling pathway. In support of our findings, observa-
tional studies have shown that estrogen therapy may sig-
nificantly decrease the risk of CAD by counteracting
oxidized LDL–induced endothelial dysfunction [44] and
by inhibiting endothelial progenitor cell senescence [45].
Other research has indicated that estrogen does not confer
protection by affecting vascular relaxation [46] and that its
protective effects may be independent of lipid levels [47].
Brunelli and colleagues [48,49] have shown that 17β-
estradiol could bind to a single specific and saturable bind-
ing site of ApoB100 and prevent the misfolding of its
structure on electronegative LDL without changing the
electronegativity and phospholipase activity of LDL.
Therefore, the modification of ApoB100 may play an im-
portant role in the underlying mechanisms by which es-
trogen provides protection, although this possibility needs
further investigation.
Regulation of TNF-α and LOX-1 expression by electro-
negative LDL and estrogen
Recently, genetic analyses performed in various animal
models have shown that phosphoinositol-3-kinase (PI3K)/
Akt, TNF-α, and other metabolic pathways are crucial for
cellular senescence [1]. Thus, it is possible that highly elec-
tronegative LDL promotes endothelial senescence by inhi-
biting the PI3K/Akt pathway and by increasing TNF-α via
LOX-1 [19]. In the present study, we found that LDL
isolated from db/db mice enhanced both LOX-1 and
TNF-α expression and that pretreatment of BAECs with
17β-estradiol and genistein significantly diminished
these effects. Our findings correspond to those previ-
ously reported showing that estrogen decreases TNF-α
expression and oxidized LDL–induced endothelial cell
dysfunction [50].
Conclusion
In conclusion, our data have suggested that, compared
with wild-type mice, the more prominent DNA damageand endothelial senescence observed in male db/db mice
may be partly attributed to more electronegative and,
thus, more toxic LDL. Furthermore, estrogens may pro-
vide systemic hormonal protection against the harmful
effects of electronegative LDL. Our findings indicate that
gender disparities in LDL-induced cardiovascular
damage may impact the development of CAD.
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